Neda Hashemi, MD, Author at Grand Rounds in Urology

Neda Hashemi, MD

Neda Hashemi, MD, is currently an associate professor within the Department of Internal Medicine, Division of Hematology Oncology, at the University of New Mexico Comprehensive Cancer Center (UNMCCC) in Albuquerque. Dr. Hashemi is a board-certified medical oncologist with a primary focus in the management of genitourinary (GU) cancers. At UNMCCC, she leads the GU working group and oversees clinical trials in GU cancers.

Dr. Hashemi earned her MD at Iran University of Medical Sciences in Tehran. She then spent two years as a clinical research fellow in neuro-oncology at the Cleveland Clinic Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center. She completed her residency in internal medicine at the University of Texas at Houston and then went on to complete her fellowship in hematology/oncology at Indiana University in Indianapolis.

Dr. Hashemi has been actively engaged in numerous trials conducted by the National Cancer Institute's (NCI's) National Clinical Trials Network, as well as collaborating with industry partners, both as a site principal investigator and co-investigator. Beyond her clinical responsibilities, Dr. Hashemi serves as the chair for the UNMCCC Protocol Review and Monitoring Committee and holds positions such as the NCI Community Oncology Research Program Representative on the NCI Prostate Cancer Task Force. She is also a member of various committees, including the SWOG GU committee and Hoosier Cancer Research Network GU committee.

Disclosures:

Talks by Neda Hashemi, MD

New Systemic Therapies for Advanced Urothelial Carcinoma

Posted by Neda Hashemi, MD | Nov 2024

Neda Hashemi, MD, presents emerging systemic therapies for advanced bladder cancer, focusing on the transformative shifts since 2023. She highlights the pivotal role of recent ESMO findings in reshaping treatment paradigms, underscoring the shift from conventional platinum-based chemotherapy to more advanced immunotherapy-based approaches.

In this 18-minute presentation, Hashmi elaborates on the importance of the EV-302 trial, noting that these advances mark a turning point in treating metastatic bladder cancer. The CheckMate 901 study, though overshadowed by EV-302, also reveals promising results. Response rates for these patients suggest potential breakthroughs in disease management.

Hashemi acknowledges the complexity of managing treatment-related toxicities and emphasizes the importance of developing strategies to manage side effects effectively. Hashmi also touches on accessibility challenges outside the US, stressing the need for personalized approaches based on regional availability.

Neda Hashemi, MD

Talks by Neda Hashemi, MD

New Systemic Therapies for Advanced Urothelial Carcinoma

Join the GRU Community

You have Successfully Subscribed!